These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

219 related articles for article (PubMed ID: 17405529)

  • 1. [Investigation on new molecular entities of drugs approved in three regions, Japan, U.S. and EU--common and preceding approvals in current 4 years].
    Saito M; Hirata-Koizumi M; Miyake S; Hasegawa R
    Kokuritsu Iyakuhin Shokuhin Eisei Kenkyusho Hokoku; 2006; (124):80-2. PubMed ID: 17405529
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Approval of new biopharmaceuticals 1999-2006: comparison of the US, EU and Japan situations.
    Tsuji K; Tsutani K
    Eur J Pharm Biopharm; 2008 Mar; 68(3):496-502. PubMed ID: 17884403
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Patent life of antiretroviral drugs approved in the US from 1987 to 2007.
    Rodriguez-Monguio R; Seoane-Vazquez E
    AIDS Care; 2009 Jun; 21(6):760-8. PubMed ID: 19499381
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical development and review times for new drugs in Japan: associated factors.
    Ishibashi T; Yasuda K; Kusama M; Sugiyama Y; Ono S
    Clin Pharmacol Ther; 2010 Oct; 88(4):487-91. PubMed ID: 20739921
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Postmarketing drug dosage changes of 499 FDA-approved new molecular entities, 1980-1999.
    Cross J; Lee H; Westelinck A; Nelson J; Grudzinskas C; Peck C
    Pharmacoepidemiol Drug Saf; 2002 Sep; 11(6):439-46. PubMed ID: 12426927
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Approval of new drugs 1999-2007: comparison of the US, the EU and Japan situations.
    Tsuji K; Tsutani K
    J Clin Pharm Ther; 2010 Jun; 35(3):289-301. PubMed ID: 20848767
    [TBL] [Abstract][Full Text] [Related]  

  • 7. New therapeutic agents marketed in 1993.
    Hussar DA
    Pa Med; 1994 Apr; 97(4):12-6. PubMed ID: 8008381
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Market withdrawal of new molecular entities approved in the United States from 1980 to 2009.
    Qureshi ZP; Seoane-Vazquez E; Rodriguez-Monguio R; Stevenson KB; Szeinbach SL
    Pharmacoepidemiol Drug Saf; 2011 Jul; 20(7):772-7. PubMed ID: 21574210
    [TBL] [Abstract][Full Text] [Related]  

  • 9. New therapeutic agents marketed in 1995.
    Hussar DA
    Pa Med; 1996 Apr; 99(4):43-6. PubMed ID: 8935886
    [TBL] [Abstract][Full Text] [Related]  

  • 10. New therapeutic agents marketed in 1993.
    Hussar DA
    Pa Med; 1994 Jun; 97(6):22-3. PubMed ID: 8065777
    [TBL] [Abstract][Full Text] [Related]  

  • 11. New therapeutic agents marketed in 1993.
    Hussar DA
    Pa Med; 1994 May; 97(5):12-7. PubMed ID: 8036027
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Fixed-Dose Combination Drug Approvals, Patents and Market Exclusivities Compared to Single Active Ingredient Pharmaceuticals.
    Hao J; Rodriguez-Monguio R; Seoane-Vazquez E
    PLoS One; 2015; 10(10):e0140708. PubMed ID: 26469277
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Approaches to Japanese dose evaluation in global drug development: factors that generate different dosages between Japan and the United States.
    Nakashima K; Narukawa M; Takeuchi M
    Clin Pharmacol Ther; 2011 Dec; 90(6):836-43. PubMed ID: 22048222
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Anticancer drug development from traditional cytotoxic to targeted therapies: evidence of shorter drug research and development time, and shorter drug lag in Japan.
    Kawabata-Shoda E; Masuda S; Kimura H
    J Clin Pharm Ther; 2012 Oct; 37(5):547-52. PubMed ID: 22428857
    [TBL] [Abstract][Full Text] [Related]  

  • 15. New drug approval times and 'therapeutic potential' in Canada, Australia, Sweden and the United States during the period 1992 to 1998.
    Rawson NS; Kaitin KI
    Can J Clin Pharmacol; 2000; 7(2):97-101. PubMed ID: 10958705
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evolving Landscape of New Drug Approval in Japan and Lags from International Birth Dates: Retrospective Regulatory Analysis.
    Tanaka M; Idei M; Sakaguchi H; Kato R; Sato D; Sawanobori K; Kawarasaki S; Hata T; Yoshizaki A; Nakamura M; Ikuma M
    Clin Pharmacol Ther; 2021 May; 109(5):1265-1273. PubMed ID: 33048367
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The notorious "drug lag" for oncology drugs in Japan.
    Yonemori K; Hirakawa A; Ando M; Hirata T; Yunokawa M; Shimizu C; Katsumata N; Tamura K; Fujiwara Y
    Invest New Drugs; 2011 Aug; 29(4):706-12. PubMed ID: 21286780
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Same drug, different dosing: differences in dosing for drugs approved in the United States, Europe, and Japan.
    Malinowski HJ; Westelinck A; Sato J; Ong T
    J Clin Pharmacol; 2008 Aug; 48(8):900-8. PubMed ID: 18524997
    [TBL] [Abstract][Full Text] [Related]  

  • 19. New therapeutic agents marketed in 1993.
    Hussar DA
    Pa Med; 1994 Jul; 97(7):16-8. PubMed ID: 7936695
    [TBL] [Abstract][Full Text] [Related]  

  • 20. 2018 in review: FDA approvals of new molecular entities.
    Kinch MS; Griesenauer RH
    Drug Discov Today; 2019 Sep; 24(9):1710-1714. PubMed ID: 31158510
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.